Regeneration of mature dermis by transplanted particulate acellular dermal matrix in a rat model of skin defect wound

Native mammalian extracellular matrix (ECM) has been made in various forms including particles, sheet and mesh which are appropriate for site-specific applications. The ECM particles are usually created by homogenization method and have a wider size distribution. This needs to be improved to produce more uniform ECM particles. In present study, we had successfully developed a method for preparing particulate acellular dermal matrix (PADM) in different gauges. The resultant PADM was approaching a rectangular parallelepiped or cubic shape, with a better or narrower size distribution than other ECM particles in previous reports. It also retained ultrastructure and functional molecules of native ECM. In vivo performances were evaluated after implantation of PADM in an acute full-thickness skin defect wound in rats. Histological analysis showed that allogeneic PADM used as dermal regeneration template could facilitate maturation and improving collagen bundle structure of regenerated dermis at the endpoint of 20 weeks post-surgery. The PADM could be used for further investigation in analyzing the impacts of cellularly and/or molecularly modified PADM on soft tissue regeneration

Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)

Background: Primary liver cancer, around 75%–85% are hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chinese people. Summary: Since the publication of Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China in June 2017, which were updated by the National Health Commission in December 2019, additional high-quality evidence has emerged from researchers worldwide regarding the diagnosis, staging, and treatment of liver cancer, that requires the guidelines to be updated again. The new edition (2022 Edition) was written by more than 100 experts in the field of liver cancer in China, which not only reflects the real-world situation in China, but also may re-shape the nationwide diagnosis and treatment of liver cancer. Key Messages: The new guideline aims to encourage the implementation of evidence-based practice, and improve the national average five-year survival rate for patients with liver cancer, as proposed in the "Health China 2030 Blueprint.